Samsung Biologics : to present at the 42nd Annual J.P. Morgan Healthcare Conference
December 26, 2023 at 12:36 pm IST
Share
Press Releases
News Brief
Samsung Biologics to present at the 42nd Annual J.P. Morgan Healthcare Conference
Registered December 26, 2023 | Modified December 26, 2023
LINKEDIN
FACEBOOK
Samsung Biologics will be participating in the 2024 J.P. Morgan Healthcare Conference in San Francisco between January 8-11. The conference is the largest and most informative healthcare investment symposium in the industry, connecting leading innovators and companies who are addressing global health and wellness challenges.
This will be Samsung Biologics' eighth year to present at the event's main track session. John Rim, CEO and President of Samsung Biologics, is scheduled to share the company's achievements in 2023 and business strategies for the new year on Tuesday, January 9th.
During the event, Samsung Biologics will also meet with investors and potential clients as the company continues to add fresh capacity and diversify its portfolio.
To arrange a meeting with the Samsung Biologics team, visit here.
Samsung Biologics will be participating in the 2024 J.P. Morgan Healthcare Conference in San Francisco between January 8-11. The conference is the largest and most informative healthcare investment symposium in the industry, connecting leading innovators and companies who are addressing global health and wellness challenges.
This will be Samsung Biologics' eighth year to present at the event's main track session. John Rim, CEO and President of Samsung Biologics, is scheduled to share the company's achievements in 2023 and business strategies for the new year on Tuesday, January 9th.
During the event, Samsung Biologics will also meet with investors and potential clients as the company continues to add fresh capacity and diversify its portfolio.
To arrange a meeting with the Samsung Biologics team, visit here.
Samsung Biologics Co. Ltd. published this content on 25 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 December 2023 07:05:36 UTC.
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.